NACT is now used more widely for patients with a poorer prognosis (e.g. with lymph node metastasis), especially in those who are likely to have a good response to such treatment, particularly those with triple‐negative [absence of oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) overexpression or gene amplification] or HER2‐positive disease [1]. The gene discussed is ERBB2; the disease is metastatic malignant neoplasm in the lymph nodes.